Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor Conferences
Precision BioSciences, a clinical-stage biotechnology firm, is set to report its Q2 2020 financial results on August 13, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Precision BioSciences, a clinical-stage biotechnology firm, is set to report its Q2 2020 financial results on August 13, 2020. The company's ARCUS® genome editing platform aims to enhance therapeutic safety and efficacy, focusing on CAR T immunotherapy and gene correction therapies for genetic diseases. Additionally, CEO Matt Kane and CMO Chris Heery will represent the company at the William Blair Biotech Focus Conference on August 6 and the BTIG Virtual Biotechnology Conference on August 10. Live presentations will be available on their official website.
Positive
- Upcoming Q2 2020 financial results could provide insights into the company's performance.
- Participation in investor conferences could enhance visibility and investor relations.
Negative
- None.
Details
News Market Reaction – DTIL
The recorded move for DTIL in the trading session of this news was +3.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform today announced it will report financial results for the second quarter of 2020 on August 13, 2020.
Matt Kane, Chief Executive Officer and co-founder of Precision along with Chris Heery, Chief Medical Officer at Precision, will also participate in the following upcoming investor conferences:
William Blair Biotech Focus Conference
Date: August 6, 2020
Fireside chat: 12:00 to 12:45 PM EDT
BTIG Virtual Biotechnology Conference
Date: August 10, 2020
Fireside chat: 10:30 – 10:55 AM EDT
Live webcasts of each presentation will be accessible on the Company’s website, www.PrecisionBiosciences.com, under the Investors & Media section.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.
Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.messier@precisionbiosciences.com
Josh Rappaport
Stern Investor Relations
josh.rappaport@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.